( ent in the off-label patient arm (p=0.0...)Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses,Health

ent in the off-label patient arm (p=0.048). The TVR rate for on-label patients was 4.5 percent versus 11.6 percent in the off- label patient arm (p=0.040). "These findings are consistent with the overall clinical evidence, which shows complex patients to have higher event rates based on their complexity," he said.

The MATRIX Registry also tracked patient outcomes with dual anti-platelet therapy. According to the results, 75 percent of the patients included in the registry adhered to a prescribed dual antiplatelet therapy out to one year. However, such compliance did not result in significant differences in the rates of mortality, heart attack or stent thrombosis after one year compared to the outcomes of patients who stopped dual anti-platelet therapy before one year.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER(R) SELECT(TM) Sirolimus-eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at www.cypherstent.com.

About Cord
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
2. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
3. Monitoring Patient Glucose Levels: New Advances in software make it easier
4. Managing Preanalytical Processes for Patient Safety
5. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
6. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery